ACADIA PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (see signature page hereto)
SIGNAT URES
Pursuant to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Acadia Pharmaceuticals Inc. | |
| Date: February 27, 2024 | /s/ Stephen R. Davis |
|---|---|
| Stephen R. DavisChief Executive Officer(on behalf of the registrant and as the registrant’sPrincipal Executive Officer) |
KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Stephen R. Davis his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /S/ STEPHEN R. DAVIS Stephen R. Davis | Chief Executive Officer and Director(Principal Executive Officer) | February 27, 2024 |
| /S/ MARK C. SCHNEYER Mark C. Schneyer | Executive Vice President and Chief Financial Officer (Principal Financial Officer) | February 27, 2024 |
| /S/ JAMES K. KIHARA James K. Kihara | Vice President, Chief Accounting Officer and Controller (Principal Accounting Officer) | February 27, 2024 |
| /S/ STEPHEN R. BIGGAR Stephen R. Biggar | Chairman of the Board | February 27, 2024 |
| /S/ JULIAN C. BAKER Julian C. Baker | Director | February 27, 2024 |
| /S/ LAURA A. BREGE Laura A. Brege | Director | February 27, 2024 |
| /S/ JAMES M. DALY James M. Daly | Director | February 27, 2024 |
| /S/ ELIZABETH A. GAROFALO Elizabeth A. Garofalo | Director | February 27, 2024 |
| /S/ EDMUND P. HARRIGAN Edmund P. Harrigan | Director | February 27, 2024 |
| /S/ ADORA NDU Adora Ndu | Director | February 27, 2024 |
| /S/ DANIEL B. SOLAND Daniel B. Soland | Director | February 27, 2024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.